In this randomized controlled clinical trial, patients with moderate to severe mitral valve
stenosis (MS) and atrial fibrillation (AF) will be enrolled into the study.Participants will
be divided into two groups based on the anticoagulation regimen type. The intervention group
will receive rivaroxaban and the control group will be given warfarin. All patients will be
observed closely during a period of one year. Through the follow up, embolic events and
hemorrhagic complications will be recorded in both groups. In addition, patients in both
group will undergo a baseline magnetic resonance imaging (MRI) and an MRI after one-year
follow up, by which the silent embolic events will be compared in both groups.
Phase:
Phase 3
Details
Lead Sponsor:
Rajaie cardiovascular medical & research center Rajaie Cardiovascular Medical and Research Center
Collaborators:
Abidi Company Abidi Pharmaceuticals National Institute for Medical research and Development (NIMAD)
Treatments:
Factor Xa Inhibitors Rivaroxaban Vitamin K Vitamin K 1 Warfarin